Advertisement
Research ArticleDrug Discovery and Translational Medicine

The novel anticancer drug hydroxytriolein inhibits lung cancer cell proliferation via a PKCα and ERK1/2 dependent mechanism

Francisca Guardiola-Serrano, Roberto Beteta-Gobel, Raquel Rodriguez-Lorca, Maitane Ibarguren, David J. Lopez, Silvia Teres, Rafael Alvarez, Maria Alonso-Sande, Xavier Busquets and Pablo Vicente Escriba
Journal of Pharmacology and Experimental Therapeutics June 11, 2015, jpet.114.222281; DOI: https://doi.org/10.1124/jpet.114.222281

Article Information

jpet.114.222281
DOI 
https://doi.org/10.1124/jpet.114.222281
PubMed 
26065701
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Published online June 11, 2015.

Article Versions

Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Francisca Guardiola-Serrano1,*,
  2. Roberto Beteta-Gobel1,
  3. Raquel Rodriguez-Lorca1,
  4. Maitane Ibarguren2,
  5. David J. Lopez2,
  6. Silvia Teres2,
  7. Rafael Alvarez1,
  8. Maria Alonso-Sande2,
  9. Xavier Busquets1, and
  10. Pablo Vicente Escriba1
  1. 1 University of the Balearic Islands;
  2. 2 University of the Balearic Islands and Lipopharma Therapeutics S.L
  1. ↵* Corresponding author; email: francisca.guardiola{at}uib.es

Statistics from Altmetric.com

Article usage

Article usage: June 2015 to September 2024

AbstractFullPdf
Jun 20151732122
Jul 20154551533
Aug 2015110518
Sep 20151234723
Oct 201569711
Nov 201573412
Dec 201538311
Jan 201631818
Feb 20162334
Mar 20163949
Apr 20162016
May 20164338
Jun 20162617
Jul 201627527
Aug 2016501520
Sep 2016141215
Oct 2016651513
Nov 2016372725
Dec 2016251721
Jan 201744422
Feb 201712218
Mar 201743834
Apr 201734523
May 201732224
Jun 201751323
Jul 201711823
Aug 201711723
Sep 20170236
Oct 201701812
Nov 201733121
Dec 20171195
Jan 201803811
Feb 20184187
Mar 201821815
Apr 201811811
May 201811310
Jun 201801311
Jul 20180168
Aug 20180113
Sep 20180119
Oct 201809112
Nov 20180606
Dec 20182577
Jan 201915616
Feb 201934118
Mar 20190178
Apr 201911631
May 201912312
Jun 20190189
Jul 201901512
Aug 201902013
Sep 201905115
Oct 20193129
Nov 201922829
Dec 2019183
Jan 20204812
Feb 2020196
Mar 2020477
Apr 2020497
May 202011610
Jun 2020153
Jul 20201125
Aug 2020187
Sep 202061920
Oct 202005312
Nov 202037417
Dec 202061913
Jan 202171315
Feb 20212189
Mar 202153319
Apr 20212217
May 2021185024
Jun 202122612
Jul 20212775
Aug 20212026
Sep 20211612
Oct 20216028
Nov 202128111
Dec 20211010
Jan 202223112
Feb 20221310
Mar 20222622
Apr 202221110
May 20221110
Jun 20221621
Jul 20223812
Aug 20222615
Sep 20224117
Oct 20222823
Nov 20222312
Dec 20222113
Jan 20232114
Feb 20231603
Mar 20235231
Apr 20233116
May 202329012
Jun 20232310
Jul 202343012
Aug 20233817
Sep 20235812
Oct 2023107110
Nov 202320611
Dec 20235917
Jan 202486214
Feb 20242352
Mar 20244836
Apr 20248558
May 20244414
Jun 20242324
Jul 20244729
Aug 20245123
Sep 20241407

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleDrug Discovery and Translational Medicine

The novel anticancer drug hydroxytriolein inhibits lung cancer cell proliferation via a PKCα and ERK1/2 dependent mechanism

Francisca Guardiola-Serrano, Roberto Beteta-Gobel, Raquel Rodriguez-Lorca, Maitane Ibarguren, David J. Lopez, Silvia Teres, Rafael Alvarez, Maria Alonso-Sande, Xavier Busquets and Pablo Vicente Escriba
Journal of Pharmacology and Experimental Therapeutics June 11, 2015, jpet.114.222281; DOI: https://doi.org/10.1124/jpet.114.222281
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement